Dr. Ready is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4101 N Roxboro St
Durham, NC 27704Phone+1 919-684-8111
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
- Roger Williams Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
- Brown UniversityResidency, Internal Medicine, 1986 - 1989
- Vanderbilt University School of MedicineClass of 1986
Certifications & Licensure
- NC State Medical License 2006 - 2025
- RI State Medical License 1988 - 2006
- MA State Medical License 1994 - 2003
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
Clinical Trials
- Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2002 May 01
- Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2004 Dec 01
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2007 Mar 15
- Join now to see all
Publications & Presentations
PubMed
- Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon 2nd
Nature Communications. 2025-01-02 - A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.Daniel Morgensztern, Neal Ready, Melissa L Johnson, Afshin Dowlati, Noura Choudhury
Clinical Cancer Research. 2024-11-15 - 2 citationsCombination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity.Hong Zheng, Xiaoqing Yu, Mohammed L Ibrahim, Dana Foresman, Mengyu Xie
Cancer Immunology Research. 2023-04-03
Press Mentions
- Targeting Innovation in Small Cell Lung CancerNovember 29th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: